Today: 18 November 2025
Subscribe
Browse Category

Medical Technology News 29 July 2025 - 3 November 2025

ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

Stock Performance & Trading Trends (2025) ClearPoint Neuro’s stock has delivered dramatic gains in 2025, transforming from a little-known small-cap into a high-flyer. The share price rallied over 300% from 2024 lows, driven by positive news in both the company’s own product line and its partners’ clinical trial successes. Notably, CLPT climbed from roughly $5.50 in May 2024 to over $19 by February 2025 nasdaq.com. After a mid-year breather, momentum returned in Q3/Q4 2025: the stock surged nearly 40% in one day on September 24, 2025 after announcing an FDA clearance (for its Prism laser) and bullish revenue guidance nasdaq.com
3 November 2025
 ·  ·  ·  · 
Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific’s Q3 report blew past expectations. Marlborough, MA-based Boston Scientific (NYSE:BSX) posted reported net income of $755 M ($0.51/share GAAP) and adjusted EPS of $0.75 timesunion.com chartmill.com, topping the $0.71–$0.72 analysts’ forecast. CEO Mike Mahoney called it “another exceptional quarter of strong performance” prnewswire.com, fueled by robust growth across all businesses. Total sales were $5.065 B, up 20.3% from a year ago prnewswire.com. Importantly, organic (same-currency) revenue grew 15.3%, well above the 12–14% guidance range. U.S. revenues surged ~27% in Q3 investing.com, reflecting strong demand for its interventional cardiology and MedSurg devices. Analysts highlighted that every major segment beat. The cardiovascular
22 October 2025
 ·  ·  ·  · 
Intuitive Surgical Stock Rockets 17% After Blowout Q3 Earnings – Is $600 Next?

Intuitive Surgical Stock Rockets 17% After Blowout Q3 Earnings – Is $600 Next?

Intuitive Surgical’s da Vinci surgical robot in an operating room setting. Intuitive’s stock jumped on Oct. 21 after the company reported blowout Q3 results and raised full-year guidance reuters.com ts2.tech. The quarter’s 23% revenue growth was driven by a surge in robot-assisted procedures, as hospitals resume elective surgeries and expand minimally-invasive care reuters.com reuters.com. Reuters notes Intuitive has seen “steady growth as hospitals work through a backlog of deferred procedures” reuters.com, reflecting post-pandemic catch-up demand. Intuitive’s CEO Dave Rosa celebrated the results. He noted “continued growth in customer use and adoption of our Ion and da Vinci platforms, including da
22 October 2025
 ·  ·  ·  ·  · 
Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Stock Performance & Analyst Consensus Intuitive’s stock has been volatile in 2025. It gained ground last week on optimism (e.g. up ~2.7% on Oct. 17) and now sits around $446 investing.com marketbeat.com. Over the past year, the price swung between about $425 and $616 investing.com. At ~$446, ISRG trades at a high single-digit P/E (~60x) compared to the medtech sector, but analysts argue much of Intuitive’s growth is already priced in. Institutional sentiment is upbeat: 22 of 32 surveyed analysts rate ISRG a Buy, with an average 12-month target of roughly $576 investing.com (implying ~29% upside). For example, RBC Capital
19 October 2025
 ·  ·  ·  ·  · 
Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Company Overview: A Near-Patient Diagnostics Specialist Bluejay Diagnostics, Inc. is a small Massachusetts-based medical diagnostics company focused on rapid near-patient testing solutions for critical care settings stocktitan.net. The company’s mission is to improve emergency and intensive care outcomes by enabling faster, point-of-care testing for life-threatening conditions like sepsis stocktitan.net. Bluejay’s flagship product-in-development is the Symphony system – an automated, “sample-to-result” analyzer that uses disposable cartridges to measure key biomarkers from a patient’s blood sample in minutes bluejaydx.com bluejaydx.com. Symphony’s first target analyte is interleukin-6 (IL-6), an inflammatory marker that rises during infection and sepsis. In hospitals today, diagnosing sepsis early
9 October 2025
 ·  ·  ·  ·  · 
MedTech Giant’s IPO Shakes Up Market: Ottobock’s Blockbuster Debut Revives IPO Hopes

MedTech Giant’s IPO Shakes Up Market: Ottobock’s Blockbuster Debut Revives IPO Hopes

Ottobock’s Blockbuster Debut in Frankfurt Ottobock’s IPO made headlines as the prosthetics manufacturer delivered a much-needed jolt to Germany’s capital market. Trading in Ottobock shares began on October 9, 2025, on the Frankfurt Stock Exchange’s Prime Standard segment. The stock’s first trade at €72.00 was significantly above the €66 per share offering price deutsche-boerse.com. That opening price equated to about a +9% “pop” for IPO investors, underscoring the high demand for the shares. In fact, Ottobock’s debut is being celebrated as “the country’s largest IPO in over a year”, according to Reuters globalbankingandfinance.com. It’s a standout given the recent scarcity of large offerings in Frankfurt. The initial
9 October 2025
 ·  ·  ·  · 
AI Just Diagnosed You—Now What? The Rise of Superhuman Doctors Made of Code

AI Just Diagnosed You—Now What? The Rise of Superhuman Doctors Made of Code

A boy in the United States with three years of chronic pain was diagnosed by an AI chatbot with spina bifida occulta, later confirmed by a specialist. Microsoft’s AI Diagnostic Orchestrator (MAI-DxO) achieved an 85% correct diagnosis rate on nearly 300 challenging NEJM case studies, compared with 20% for 21 experienced physicians, while ordering 20% fewer tests. Google’s conversational diagnostic AI prototype outperformed physicians on hypothetical primary care cases, scoring about 59% accuracy versus 33% for human doctors. PathAI announced a major 2024 partnership with Quest Diagnostics, with Quest acquiring PathAI’s laboratory and integrating AI across its pathology labs. IDx-DR
29 July 2025
 ·  ·  ·  · 
Go toTop